SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (614)1/28/2003 4:44:05 PM
From: JMarcus  Read Replies (1) of 7424
 
ALLP.OB surged 33.3% on news that it Baxter has granted it an option to buy back the rights to ALLP's blood substitute (oxygen therapeutic), Oxygent. ALLP also announced that it has retained Burrill & Company to help it find a new partner to fund pending international Phase 3 clinical studies with Oxygent. ALLP also said that it has obtained regulatory and clinical site approvals in select European countries to commence the Phase 3 protocol, which was designed using data from a successful multinational Phase 3 study with general surgery patients as reported in the journal Anesthesiology last month.

Hope springs eternal. The shares I bought a few years ago, when the company had three drugs in pivotal trials, have lost 99.5% of their value.

Marc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News